RBC Capital Markets adjusted its price target for Amgen (NASDAQ:AMGN) shares, reducing it slightly from $324 to $320, while retaining an Outperform rating on the biotechnology firm's stock. The ...
RBC Capital analysts confirmed their positive stance on Alphabet Inc. (NASDAQ:GOOGL) shares, maintaining an Outperform rating ...